Therapeutic Vaccination for HPV-Mediated Cancers

Flora Yan, Lindsay G. Cowell, Anna Tomkies, Andrew T. Day

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Purpose of Review: The goal of this narrative review is to educate clinicians regarding the foundational concepts, efficacy, and future directions of therapeutic vaccines for human papillomavirus (HPV)–mediated cancers. Recent Findings: Therapeutic HPV vaccines deliver tumor antigens to stimulate an immune response to eliminate tumor cells. Vaccine antigen delivery platforms are diverse and include DNA, RNA, peptides, proteins, viral vectors, microbial vectors, and antigen-presenting cells. Randomized, controlled trials have demonstrated that therapeutic HPV vaccines are efficacious in patients with cervical intraepithelial neoplasia. In patients with HPV-mediated malignancies, evidence of efficacy is limited. However, numerous ongoing studies evaluating updated therapeutic HPV vaccines in combination with immune checkpoint inhibition and other therapies exhibit significant promise. Summary: Therapeutic vaccines for HPV-mediated malignancies retain a strong biological rationale, despite their limited efficacy to date. Investigators anticipate they will be most effectively used in combination with other regimens, such as immune checkpoint inhibition.

Original languageEnglish (US)
Pages (from-to)44-61
Number of pages18
JournalCurrent Otorhinolaryngology Reports
Issue number1
StatePublished - Mar 2023


  • Cancer
  • Human papillomavirus
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Surgery
  • Immunology and Allergy
  • Otorhinolaryngology
  • Clinical Neurology


Dive into the research topics of 'Therapeutic Vaccination for HPV-Mediated Cancers'. Together they form a unique fingerprint.

Cite this